Anthony Letai

USPTO Granted Patents = 14 (Patent Applications = 7)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 1.8

ph-index = 7

Forward Citations = 203(Granted Patents)

Company Filing History:

13 out of 1,209

Dana-farber-cancer Institute Inc.

patents

1 out of 12

Eutropics Pharmaceuticals, Inc.

patents

1 out of 118

Howard Hughes Medical Institute

patents

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11867688 - High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells (2024-01-09),

2. 11867687 - Methods of BH3 profiling (2024-01-09),

3. 11815508 - Dynamic BH3 profiling (2023-11-14),

4. 11225511 - BH3 peptides and methods of use thereof (2022-01-18),

5. 11215608 - Methods of determining cellular chemosensitivity (2022-01-04),

6. 10761086 - High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells (2020-09-01),

7. 10739333 - Methods of BH3 profiling (2020-08-11),

8. 10393733 - Dynamic BH3 profiling (2019-08-27),

9. 9902759 - BH3 peptides and methods of use thereof (2018-02-27),

10. 9856303 - BH3 peptides and method of use thereof (2018-01-02),

11. 9540674 - Methods of determining cellular chemosensitivity (2017-01-10),

12. 8221966 - Methods of determining cellular chemosensitivity (2012-07-17),

13. 8168755 - Antibodies specific to heterodimers of Bcl-2 family and uses thereof (2012-05-01),

14. 7868133 - BH3 peptides and method of use thereof (2011-01-11),

Title: Innovations and Contributions of Inventor Anthony Letai

Introduction

Anthony Letai is a prominent inventor based in Medfield, MA (US), known for his significant contributions to the field of cancer research. With a total of 14 patents, Letai has developed innovative methods that enhance our understanding of cell sensitivity to therapeutic agents.

Latest Patents

Among his latest patents, Letai has introduced groundbreaking methods of BH3 profiling. The first patent provides methods for determining cell sensitivity to a therapeutic agent, which is crucial for personalized medicine. The second patent, titled "High throughput BH3 profiling," presents a rapid and scalable technology to BH3 profile on low numbers of cells. This invention relates to predicting cell sensitivity to a test agent, with applications in various therapeutic contexts.

Career Highlights

Throughout his career, Letai has worked with esteemed organizations such as Dana-Farber Cancer Institute and Eutropics Pharmaceuticals, Inc. His work in these institutions has allowed him to collaborate with leading experts in the field, further advancing cancer research and treatment methodologies.

Collaborations

Letai has collaborated with notable colleagues, including Jeremy Ryan and Stanley J. Korsmeyer. These partnerships have fostered a rich environment for innovation and discovery in cancer therapeutics.

Conclusion

Anthony Letai's contributions to cancer research through his innovative patents and collaborations highlight his role as a key figure in the scientific community. His work continues to pave the way for advancements in understanding and treating cancer.

This text is generated by artificial intelligence and may not be accurate.